DURECT Corp (Durect) focuses on the development of pharmaceutical products based on its drug delivery technology platforms. The company’s pharmaceutical systems enable optimized therapy for a given disease by controlling the rate and duration of drug administration. The company operates through one operating segment, which includes research, development and manufacturing of pharmaceutical products. Durect markets two product lines, including Alzet, an osmotic pump; and Lactel, a biodegradable polymer.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company's (R&D) efforts focus on the application of its pharmaceutical systems technologies to potential products in disease areas including pain, central nervous system (CNS) disorders, cardiovascular disease, ophthalmic and other chronic diseases. Major technology include Saber, Oradur and Cloud. Key pipeline products include five investigational drug programs. In FY2022, the company spent US$36.9 million on its R&D activities, which stood at 191.3% of its revenue and grew 16% YoY. Consist of 25 issued US patents, 170 foreign patents, 30 pending US patents and 190 foreign applications pending.